![Transparency Market Researchが調査・発行した産業分析レポートです。世界の幹細胞市場2021年ｰ2028年：製品種類別（成体幹細胞、ヒト胚性幹細胞、人工多能性幹細胞、その他）、ソース別、用途別、エンドユーザー別 / Stem Cells Market (Product Type: Adult Stem Cell, Human Embryonic Stem Cell, Induced Pluripotent Stem Cell, and Others; Source: Autologous and Allogenic; Application: Regenerative Medicines [Neurology, Oncology, Cardiology, and Others] and Drug Discovery & Development; and End-user: Therapeutics Companies, Cell & Tissue Banks, Tools & Reagents Companies, and Service Companies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028 / MRC2204A187資料のイメージです。](https://www.marketresearch.co.jp/images-folder2/99x123xreport-contents-71.gif.pagespeed.ic.cYgo-ZH9PJ.jpg) | • レポートコード：MRC2204A187 • 出版社/出版日：Transparency Market Research / 2022年1月 • レポート形態：英文、PDF、180ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の本調査レポートは、世界の幹細胞市場について調査し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、主要インサイト、製品種類別（成体幹細胞、ヒト胚性幹細胞、人工多能性幹細胞、その他）分析、ソース別分析、用途別分析、エンドユーザー別分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などを掲載しています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・主要インサイト ・世界の幹細胞市場規模：製品種類別（成体幹細胞、ヒト胚性幹細胞、人工多能性幹細胞、その他） ・世界の幹細胞市場規模：ソース別 ・世界の幹細胞市場規模：用途別 ・世界の幹細胞市場規模：エンドユーザー別 ・世界の幹細胞市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ） ・競争状況 |
Stem Cells Market – Scope of Report
TMR’s report on the global stem cells market studies past as well as current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2028. The report provides revenue of the global stem cells market for the period 2017–2028, considering 2020 as the base year and 2028 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global stem cells market during the forecast period.
The report has been prepared after an extensive primary and secondary research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global stem cells market.
Secondary research also included Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various phenomenon in the global stem cells market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global stem cells market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global stem cells market.
The report delves into the competition landscape of the global stem cells market. Key players operating in the global stem cells market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global stem cells market that have been profiled in this report.
Key Questions Answered in Stem Cells Market Report
What is the scope of growth of product companies in the global stem cells market?
What will be the Y-o-Y growth of the global stem cells market between 2017 and 2028?
What is the influence of changing trends in technologies on the global stem cells market?
Will North America be the most profitable market for stem cells devices providers?
Which factors are anticipated to hamper the growth of the global stem cells market during the forecast period?
Which are the leading companies in the global stem cells market?
Research Methodology
A unique research methodology has been utilized by TMR to conduct comprehensive research on the growth of the global stem cells market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.
Secondary methods referred to by analysts during the production of the global stem cells market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR’s study on the stem cells market as primary methods.
These primary and secondary methods have provided exclusive information during interviews, which serves as a validation from the stem cells market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global stem cells market with accuracy. The study also uses the top-down approach to assess the revenue for each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR’s estimates on future prospects of the global stem cells market more reliably and accurately.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Stem Cells Market
4. Market Overview
4.1. Introduction
4.1.1. Product Type Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Stem Cells Market Analysis and Forecast, 2017–2028
4.4.1. Market Revenue Projections (US$ Mn)
4.4.2. Market Volume/Unit Shipments Projections
5. Key Insights
5.1. Disease Prevalence & Incidence Rate globally with key countries
5.2. Key Industry Developments
5.3. Pipeline Analysis
5.4. COVID-19 Impact Analysis
6. Global Stem Cells Market Analysis and Forecast, by Product Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Product Type, 2017–2028
6.3.1. Adult Stem Cell
6.3.2. Human Embryonic Stem Cell
6.3.3. Induced Pluripotent Stem Cell
6.3.4. Others
6.4. Market Attractiveness Analysis, by Product Type
7. Global Stem Cells Market Analysis and Forecast, by Source
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Source, 2017–2028
7.3.1. Autologous
7.3.2. Allogenic
7.4. Market Attractiveness Analysis, by Source
8. Global Stem Cells Market Analysis and Forecast, by Application
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Application, 2017–2028
8.3.1. Regenerative Medicines
8.3.1.1. Neurology
8.3.1.2. Oncology
8.3.1.3. Cardiology
8.3.1.4. Others
8.3.2. Drug Discovery & Development
8.4. Market Attractiveness Analysis, by Application
9. Global Stem Cells Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by End-user, 2017–2028
9.3.1. Therapeutics Companies
9.3.2. Cell & Tissue Banks
9.3.3. Tools & Reagents Companies
9.3.4. Service Companies
9.4. Market Attractiveness Analysis, by End-user
10. Global Stem Cells Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Country/Region
11. North America Stem Cells Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product Type, 2017–2028
11.2.1. Adult Stem Cell
11.2.2. Human Embryonic Stem Cell
11.2.3. Induced Pluripotent Stem Cell
11.2.4. Others
11.3. Market Value Forecast, by Source, 2017–2028
11.3.1. Autologous
11.3.2. Allogenic
11.4. Market Value Forecast, by Application, 2017–2028
11.4.1. Regenerative Medicines
11.4.1.1. Neurology
11.4.1.2. Oncology
11.4.1.3. Cardiology
11.4.1.4. Others
11.4.2. Drug Discovery & Development
11.5. Market Value Forecast, by End-user, 2017–2028
11.5.1. Therapeutics Companies
11.5.2. Cell & Tissue Banks
11.5.3. Tools & Reagents Companies
11.5.4. Service Companies
11.6. Market Value Forecast, by Country, 2017–2028
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Product Type
11.7.2. By Source
11.7.3. By Application
11.7.4. By End-user
11.7.5. By Country
12. Europe Stem Cells Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product Type, 2017–2028
12.2.1. Adult Stem Cell
12.2.2. Human Embryonic Stem Cell
12.2.3. Induced Pluripotent Stem Cell
12.2.4. Others
12.3. Market Value Forecast, by Source, 2017–2028
12.3.1. Autologous
12.3.2. Allogenic
12.4. Market Value Forecast, by Application, 2017–2028
12.4.1. Regenerative Medicines
12.4.1.1. Neurology
12.4.1.2. Oncology
12.4.1.3. Cardiology
12.4.1.4. Others
12.4.2. Drug Discovery & Development
12.5. Market Value Forecast, by End-user, 2017–2028
12.5.1. Therapeutics Companies
12.5.2. Cell & Tissue Banks
12.5.3. Tools & Reagents Companies
12.5.4. Service Companies
12.6. Market Value Forecast, by Country/Sub-region, 2017–2028
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Product Type
12.7.2. By Source
12.7.3. By Application
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Stem Cells Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product Type, 2017–2028
13.2.1. Adult Stem Cell
13.2.2. Human Embryonic Stem Cell
13.2.3. Induced Pluripotent Stem Cell
13.2.4. Others
13.3. Market Value Forecast, by Source, 2017–2028
13.3.1. Autologous
13.3.2. Allogenic
13.4. Market Value Forecast, by Application, 2017–2028
13.4.1. Regenerative Medicines
13.4.1.1. Neurology
13.4.1.2. Oncology
13.4.1.3. Cardiology
13.4.1.4. Others
13.4.2. Drug Discovery & Development
13.5. Market Value Forecast, by End-user, 2017–2028
13.5.1. Therapeutics Companies
13.5.2. Cell & Tissue Banks
13.5.3. Tools & Reagents Companies
13.5.4. Service Companies
13.6. Market Value Forecast, by Country/Sub-region, 2017–2028
13.6.1. Japan
13.6.2. China
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of APAC
13.7. Market Attractiveness Analysis
13.7.1. By Product Type
13.7.2. By Source
13.7.3. By Application
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Latin America Stem Cells Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product Type, 2017–2028
14.2.1. Adult Stem Cell
14.2.2. Human Embryonic Stem Cell
14.2.3. Induced Pluripotent Stem Cell
14.2.4. Others
14.3. Market Value Forecast, by Source, 2017–2028
14.3.1. Autologous
14.3.2. Allogenic
14.4. Market Value Forecast, by Application, 2017–2028
14.4.1. Regenerative Medicines
14.4.1.1. Neurology
14.4.1.2. Oncology
14.4.1.3. Cardiology
14.4.1.4. Others
14.4.2. Drug Discovery & Development
14.5. Market Value Forecast, by End-user, 2017–2028
14.5.1. Therapeutics Companies
14.5.2. Cell & Tissue Banks
14.5.3. Tools & Reagents Companies
14.5.4. Service Companies
14.6. Market Value Forecast, by Country/Sub-region, 2017–2028
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of LATAM
14.7. Market Attractiveness Analysis
14.7.1. By Product Type
14.7.2. By Source
14.7.3. By Application
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Middle East & Africa Stem Cells Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Product Type, 2017–2028
15.2.1. Adult Stem Cell
15.2.2. Human Embryonic Stem Cell
15.2.3. Induced Pluripotent Stem Cell
15.2.4. Others
15.3. Market Value Forecast, by Source, 2017–2028
15.3.1. Autologous
15.3.2. Allogenic
15.4. Market Value Forecast, by Application, 2017–2028
15.4.1. Regenerative Medicines
15.4.1.1. Neurology
15.4.1.2. Oncology
15.4.1.3. Cardiology
15.4.1.4. Others
15.4.2. Drug Discovery & Development
15.5. Market Value Forecast, by End-user, 2017–2028
15.5.1. Therapeutics Companies
15.5.2. Cell & Tissue Banks
15.5.3. Tools & Reagents Companies
15.5.4. Service Companies
15.6. Market Value Forecast, by Country/Sub-region, 2017–2028
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of MEA
15.7. Market Attractiveness Analysis
15.7.1. By Product Type
15.7.2. By Source
15.7.3. By Application
15.7.4. By End-user
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (by tier and size of companies)
16.2. Market Share/Ranking Analysis, by Company, 2020
16.3. Company Profiles
16.3.1. STEMCELL Technologies, Inc.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Financial Overview
16.3.1.3. Product Portfolio
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Astellas Pharma, Inc.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Financial Overview
16.3.2.3. Product Portfolio
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Cellular Engineering Technologies, Inc.
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Financial Overview
16.3.3.3. Product Portfolio
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. BioTime, Inc.
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Financial Overview
16.3.4.3. Product Portfolio
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Takara Bio, Inc.
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Financial Overview
16.3.5.3. Product Portfolio
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. U.S. Stem Cell, Inc.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Financial Overview
16.3.6.3. Product Portfolio
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. BrainStorm Cell Therapeutics, Inc.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Financial Overview
16.3.7.3. Product Portfolio
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Cytori Therapeutics, Inc.
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Financial Overview
16.3.8.3. Product Portfolio
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Osiris Therapeutics, Inc.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Financial Overview
16.3.9.3. Product Portfolio
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Caladrius Biosciences, Inc.
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Financial Overview
16.3.10.3. Product Portfolio
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
16.3.11. Other Prominent Players
Table 01: Global Stem Cells Market Size (US$ Mn) Forecast, by Product Type, 2017–2028
Table 02: Global Stem Cells Market Size (US$ Mn) Forecast, by Source, 2017–2028
Table 03: Global Stem Cells Market Size (US$ Mn) Forecast, by Application, 2017–2028
Table 04: Global Stem Cells Market Size (US$ Mn) Forecast, by Application – Regenerative Medicine, 2017–2028
Table 05: Global Stem Cells Market Size (US$ Mn) Forecast, by End-user, 2017–2028
Table 06: Global Stem Cells Market Size (US$ Mn) Forecast, by Region, 2017–2028
Table 07: North America Stem Cells Market Size (US$ Mn) Forecast, by Country, 2017–2028
Table 08: North America Stem Cells Market Size (US$ Mn) Forecast, by Product, 2017–2028
Table 09: North America Stem Cells Market Size (US$ Mn) Forecast, by Source, 2017–2028
Table 10: North America Stem Cells Market Size (US$ Mn) Forecast, by Application, 2017–2028
Table 11: North America Stem Cells Market Size (US$ Mn) Forecast, by Regenerative Medicine, 2017–2028
Table 12: North America Stem Cells Market Size (US$ Mn) Forecast, by Source, 2017–2028
Table 13: Europe Stem Cells Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2028
Table 14: Europe Stem Cells Market Size (US$ Mn) Forecast, by Product, 2017–2028
Table 15: Europe Stem Cells Market Size (US$ Mn) Forecast, by Source, 2017–2028
Table 16: Europe Stem Cells Market Size (US$ Mn) Forecast, by Application, 2017–2028
Table 17: Europe Stem Cells Market Size (US$ Mn) Forecast, by Regenerative Medicine, 2017–2028
Table 18: Europe Stem Cells Market Size (US$ Mn) Forecast, by Source, 2017–2028
Table 19: Asia Pacific Stem Cells Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2028
Table 20: Asia Pacific Stem Cells Market Size (US$ Mn) Forecast, by Product, 2017–2028
Table 21: Asia Pacific Stem Cells Market Size (US$ Mn) Forecast, by Source, 2017–2028
Table 22: Asia Pacific Stem Cells Market Size (US$ Mn) Forecast, by Application, 2017–2028
Table 23: Asia Pacific Stem Cells Market Size (US$ Mn) Forecast, by Regenerative Medicine, 2017–2028
Table 24: Asia Pacific Stem Cells Market Size (US$ Mn) Forecast, by Source, 2017–2028
Table 25: Latin America Stem Cells Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2028
Table 26: Latin America Stem Cells Market Size (US$ Mn) Forecast, by Product Type, 2017–2028
Table 27: Latin America Stem Cells Market Size (US$ Mn) Forecast, by Source, 2017–2028
Table 28: Latin America Stem Cells Market Size (US$ Mn) Forecast, by Application, 2017–2028
Table 29: Latin America Stem Cells Market Size (US$ Mn) Forecast, by Application – Regenerative Medicine, 2017–2028
Table 30: Latin America Stem Cells Market Size (US$ Mn) Forecast, by Source, 2017–2028
Table 31: Middle East & Africa Stem Cells Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2028
Table 32: Middle East & Africa Stem Cells Market Size (US$ Mn) Forecast, by Product Type, 2017–2028
Table 33: Middle East & Africa Stem Cells Market Size (US$ Mn) Forecast, by Source, 2017–2028
Table 34: Middle East & Africa Stem Cells Market Size (US$ Mn) Forecast, by Application, 2017–2028
Table 35: Middle East & Africa Stem Cells Market Size (US$ Mn) Forecast, by Application – Regenerative Medicine, 2017–2028
Table 36: Middle East & Africa Stem Cells Market Size (US$ Mn) Forecast, by Source, 2017–2028